Impact of TCF3 Rearrangement on CNS Relapse in Egyptian Pediatric Acute Lymphoblastic Leukemia

Elgendi, Hoda Mohammed; Abdelmaksoud, Abeer A.; Eissa, Doaa G; Abusikkien, Samy A

doi:10.3109/08880018.2014.935837

Cited by 7 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is considered an intermediate risk lesion in B-ALL as patients have favorable outcomes with modern, intensified chemotherapy regimens, but is reportedly associated with an increased risk of CNS relapse. 8,[13][14][15] TCF3-PBX1 has been previously reported in several B-LLy patients. 16,17 All patients with TCF3-PBX1 fusion-positive B-LLy in prior studies had Stage III or IV disease, consistent with this group in which both patients had stage IV disease.…”

Section: Discussionmentioning

confidence: 82%

“…The TCF3-PBX1 fusion (t(1;19)(q23;p13)) is well described in B-ALL, occurring in 2-5% of pediatric B-ALL cases. This is considered an intermediate risk lesion in B-ALL as patients have favorable outcomes with modern, intensified chemotherapy regimens, but is reportedly associated with an increased risk of CNS relapse 8,13–15 . TCF3-PBX1 has been previously reported in several B-LLy patients 16,17 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

B-Lymphoblastic Lymphoma in Children: A Case Series From a Single Institution

Devine,

Trivedi,

Reilly

2024

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

Background: Pediatric B-lymphoblastic lymphoma is an uncommon subtype of non-Hodgkin lymphoma. Studies regarding the biology, clinical course, and approach to relapse are limited. Observations: We present a series of children with B-lymphoblastic lymphoma to describe the clinical course at diagnosis and relapse as well as the role of tumor cytogenetics, immunotherapy, and hematopoietic stem cell transplant. Conclusions: The prognostic significance of cytogenetic changes in B-lymphoblastic lymphoma is not well described but may offer improved risk stratification. Immunotherapy may offer salvage options for relapsed disease and can serve as a bridge to transplant.

show abstract

Section: Discussionmentioning

confidence: 82%

Section: Discussionmentioning

confidence: 99%

B-Lymphoblastic Lymphoma in Children: A Case Series From a Single Institution

Devine,

Trivedi,

Reilly

2024

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

show abstract

Central nervous system niche involvement in the leukemia

et al. 2015

View full text Add to dashboard Cite

Central nervous system (CNS) impairment is commonly involved in leukemia, as it can be observed upon onset or relapse of the disease. It is associated with poor prognosis and is a challenging clinical problem. The objective of this paper was to provide a characterization of the CNS niche in leukemia, to elucidate the culprits of CNS involvement, including diagnostic micro RNAs (miRs) and early leukemia prognosis. CNS niche is a proper location for homing of leukemic stem cells, thus representing a candidate target in the treatment of leukemia. Recent advances in the study of leukemia hallmarks have enlightened miRs as novel biomarkers for diagnosis and detection of CNS involvement in leukemia, thus providing the opportunity to develop novel therapeutic approaches. Given the importance of prognosis and early diagnosis of CNS involvement in leukemias as well as the severe side effects of current treatments, diagnostic and therapeutic approaches should focus on identification and inhibition of the factors contributing to CNS involvement, including CXCR3, P-selectin glycoprotein ligand-1 and MCP1. MiRs such as miR-221 and miR-222 are emerging as potential tools for an innovative non-invasive therapy of CNS in leukemia affected patients.

show abstract

High Frequency and Poor Prognosis of Late Childhood BCR-ABL-Positive and MLL-AF4-Positive ALL Define the Need for Advanced Molecular Diagnostics and Improved Therapeutic Strategies in Pediatric B-ALL in Pakistan

et al. 2015

View full text Add to dashboard Cite

This study reports the highest ethnic frequency of BCR-ABL FO in pediatric ALL, and is consistent with previous reports from our region. Poor prognosis BCR-ABL and MLL-AF4 was detected in two-thirds of pediatric B-ALL and is likely to be the reason for the already reported poor survival of childhood ALL in South-East Asia. Furthermore, MLL-AF4, usually most common in infants, presented in later childhood in most of the ALL patients, which was one of the unique findings in our study. The results presented here highlight the need for mandatory inclusion of molecular testing for pediatric ALL patients in clinical decision making, together with the incorporation of tyrosine kinase inhibitors, as well as hematopoietic stem cell transplantation facilities, to improve treatment outcome for patients in developing countries.

show abstract

Impact of TCF3 Rearrangement on CNS Relapse in Egyptian Pediatric Acute Lymphoblastic Leukemia

Abstract: Analysis of TCF3 rearrangement [t(1;19) (q23;p13)] at diagnosis may provide a valuable target for modified and intensified CNS-directed chemotherapeutic protocol aiming to improve the patients' outcome.

Cited by 7 publications

References 15 publications

B-Lymphoblastic Lymphoma in Children: A Case Series From a Single Institution

B-Lymphoblastic Lymphoma in Children: A Case Series From a Single Institution

Central nervous system niche involvement in the leukemia

High Frequency and Poor Prognosis of Late Childhood BCR-ABL-Positive and MLL-AF4-Positive ALL Define the Need for Advanced Molecular Diagnostics and Improved Therapeutic Strategies in Pediatric B-ALL in Pakistan

Contact Info

Product

Resources

About